BPC157+TB500 (Wolverine) specifications and research profile
Specifications summary
| Designation | Two-component peptide research blend |
|---|---|
| Also known as | BPC-157 + TB-500 research blend |
| Sequence / composition | 5mg BPC-157 + 5mg TB-500 |
| Strength | 10mg |
| Presentation | Powder vial |
| Purity | 99%+ HPLC |
| Storage | Store refrigerated at 2-8 C, protected from light. |
| COA | View BPC-157/TB-500 10mg COA - 5 June 2026 |
Description and research context
Wolverine is a documented combination of BPC-157 and TB-500 research components rather than a single molecular entity. The combined format is intended for controlled blend-versus-component comparison.
Published component studies include BPC-157 experiments involving fibroblast migration and FAK-paxillin signalling, plus thymosin-beta-derived peptide studies involving actin binding and cell migration. These component findings do not establish a unified mechanism for the blend.
Applications in research
- Blend-versus-component analytical and cell-based comparisons
- Fibroblast migration and FAK-paxillin pathway assays
- Actin-binding, cytoskeletal and cell-motility research models
Precautions and interpretation
For controlled laboratory research only. Not for human or veterinary use. The cited findings come from specific biochemical, cellular, structural or preclinical models and must not be treated as usage guidance or evidence of a defined outcome outside those models.
BPC157+TB500 (Wolverine) research record
Clear product, batch, storage, dispatch and document information for this powder vial.
Research context
Wolverine is listed as a two-component blend for laboratory models involving peptide stability, cell-migration signalling, and matrix-pathway observations.
Composition
Each vial is represented as a 10mg blend: 5mg BPC-157 and 5mg TB500.
Use restriction
For laboratory research use only. Not for human or veterinary consumption. No use instructions or therapeutic guidance is provided.